Lonsurf Cost, Side Effects, Dosage for Colorectal Cancer Treatment

Lonsurf side effects, cost/price, dosage for advanced colon cancer or metastatic colorectal cancer treatment. Lonsurf (trifluridine, tipiracil) is a new medicine by by Taiho Oncology Inc. You can also checkout the Lonsurf FDA approval in US, dosing and full prescribing information.

Lonsurf is manufactured by Taiho Oncology Inc. in Princeton, New Jersey. The USA Food and Drug Administration approved Lonsurf(trifluridine and tipiracil) on September 22, 2015 for patients suffering from advance colorectal cancer, who are no longer responding to other therapies.

Colon/Colorectal Cancer is one of the most leading cause of death across the world. It is third most common non-skin cancer in United States.In most cases colon cancer begin as small, non cancerous clumps which are termed as adenomatous polyps. If these adenomatous polyps left untreated they will be turned into colon cancers.Commonly observed sign and symptoms of colorectal cancer are change in bowel habits, diarrhea, rectal bleeding, unexplained weight loss, fatigue, weakness, gas or pain.

Trifluridine and Tipiracil are the generic combination substances of Lonsurf drugs. Trifluridine is nucleoside analogue that inhibits the growth of tumor cells when incorporated into DNA.Tipiracil is thymidine phosphorylase inhibitor.It prevents the degradation of trifluidine during its oral administration.

Lonsurf Cost, Side Effects, Dosage for Colorectal Cancer Treatment

FDA approves the combination of these two drugs due to their synergistic effect.The efficacy and safety of Lonsurf were evaluated in an international, randomized, double-blind study involving 800 patients with previously treated metastatic colorectal cancer.

Lonsurf is indicated for metastatic colorectal cancer in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Lonsurf Cost, Side Effects, Dosage for Colorectal Cancer Treatment

Let’s have a look at Lonsurf cost, side effects and dosage for colorectal cancer treatment:

Lonsurf Side Effects in Colorectal Cancer Treatment

According to clinical trials most common Lonsurf side effects are given as follows:

• Anemia, all grades (77%)
• Neutropenia, all grades (67%)
• Asthenia/fatigue, all grades (52%)
• Nausea, all grades (48%)
• Thrombocytopenia, all grades (42%)
• Decreased appetite, all grades (39%)
• Diarrhea, all grades (32%)
• Vomiting, all grades (28%)
• Neutropenia, grades 3-4 (11-27%)
• Abdominal pain, all grades (21%)
• Pyrexia, all grades (19%)
• Anemia, grade 3 (18%)

Some rarely observed Lonsurf side effects include:

• Stomatitis, all grades (8%)
• Dysgeusia (7%)
• Alopecia (7%)
• Asthenia/fatigue, grades 3-4 (7%)
• Thrombocytopenia, grades 3-4 (1-5%)
• Decreased appetite, grades 3-4 (4%)
• Diarrhea, grades 3-4 (3%)
• Vomiting, grades 3-4 (2%)
• Abdominal pain, grades 3-4 (2%)
• Nausea, grades 3-4 (2%)
• Pyrexia, grades 3-4 (1%)

Lonsurf Cost/Price for Cancer Treatment and Dosage

This drug is specialty medication so it is categorized as expensive item.

• A typical fill can cost $4,498 or more for 30 tablets of Lonsurf 15mg/6.14mg

• while a  typical fill can cost $5,995 or more for 30 tablets of Lonsurf 20mg/8.19mg

Lonsurf Dosage/Dosing

Tipiracil/trifluridine will be available as oncology drug for cancer treatment, as an oral Lonsurf tablet. The recommended oral Lonsurf dosage are 6.14mg/15mg and 8.19mg/20mg.

Lonsurf Dose is based on trifluridine component rounded to the nearest 5-mg increment. Lonsurf is administered BID on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. Starting dose with 35 mg/m² PO it may be increased up to 80 mg/m² PO administered in the morning and evening after within 1 hour taking meal.

Lonsurf Uses in Colorectal Cancer Treatment

Lonsurf uses in colorectal cancer treatment is approved by FDA as an oral anti-cancer drug on September 22, 2015. It is used in metastatic colorectal cancer or advance colorectal cancer, for patients who are not responding to other anti-cancer drugs.